Pharminent

Sanofi pegs U.S. drug price rises to below healthcare inflation

(Reuters) – French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances.

http://www.reuters.com/article/us-sanofi-usa-idUSKBN1851HA

Filed under: Pricing